Last $82.01 USD
Change Today -1.88 / -2.24%
Volume 62.8K
GEVA On Other Exchanges
As of 11:04 AM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

synageva biopharma corp (GEVA) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/28/14 - $119.42
52 Week Low
08/20/13 - $44.52
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

synageva biopharma corp (GEVA) Related Businessweek News

No Related Businessweek News Found

synageva biopharma corp (GEVA) Details

Synageva BioPharma Corp. operates as a biopharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The company’s lead program include sebelipase alfa, a recombinant form of human lysosomal acid lipase (LAL), which is under Phase III clinical trials for the treatment of LAL deficiency in infants, children, and adults. It also has various other research programs in various stages of preclinical development, including SBC-103, an enzyme replacement therapy for lysosomal storage diseases, known as mucopolysaccharidosis type IIIB, as well as protein therapeutic programs for rare life-threatening diseases. The company was founded in 1996 and is headquartered in Lexington, Massachusetts.

172 Employees
Last Reported Date: 03/4/14
Founded in 1996

synageva biopharma corp (GEVA) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: $601.1K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $360.5K
Chief Medical Officer, Head of Research & Dev...
Total Annual Compensation: $380.1K
Executive Vice President of Medical and Regul...
Total Annual Compensation: $379.6K
Senior Vice President of Global Technical Ope...
Total Annual Compensation: $320.0K
Compensation as of Fiscal Year 2013.

synageva biopharma corp (GEVA) Key Developments

Synageva Biopharma Corp. Reports Positive Top-Line Results from Phase 3 Study of Sebelipase Alfa in Children and Adults with Lal Deficiency

Synageva BioPharma Corp. announced that the global, randomized, double-blind, placebo-controlled Phase 3 ARISE trial of sebelipase alfa in 66 children and adults with lysosomal acid lipase deficiency (LAL Deficiency) met the primary endpoint of normalization of alanine aminotransferase (ALT), a marker of liver injury (p=0.027). In addition, sebelipase alfa significantly improved multiple other disease-related abnormalities as measured by a number of secondary endpoints. LAL Deficiency patients enrolled in the trial presented with multiple clinically important abnormalities at baseline. Fibrosis and/or cirrhosis was documented in 100% (32/32) of patients who had baseline biopsies even though the median age of patients enrolled in the trial was only 13 years. Dyslipidemia was common at baseline, with a median LDL cholesterol of 204 mg/dl (which is in the very high category of >190 mg/dl), and an abnormally low median HDL cholesterol of 32.5 mg/dl.

Synageva BioPharma Corp. - Special Call

To review the top-line results from Phase 3 Study Of Sebelipase Alfa in Children and Adults with LAL Deficiency

Synageva BioPharma Corp. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-11-2014 09:20 AM

Synageva BioPharma Corp. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-11-2014 09:20 AM. Venue: Terranea Resort in Rancho Palos Verdes, 100 Terranea Way, Los Angeles, California, United States. Speakers: Sanj K. Patel, Chief Executive Officer, President, Secretary and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEVA:US $82.01 USD -1.88

GEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GEVA.
View Industry Companies

Industry Analysis


Industry Average

Valuation GEVA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 267.1x
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 223.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNAGEVA BIOPHARMA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at